CA
NZ
UK
AU
IND
US
Income from operations reached $164.1 million compared with $9.5 million a year earlier.Net Incomewas $183.3 million, or $1.20 per diluted share, versus $24.8 million, or $0.16. Operating expenses fell to $484.4 million from $515.4 million, led by a drop in sales andMarketingspending.
Sabra is a real estateInvestmenttrust that owns healthcare properties across the U.S. and Canada, including skilled nursing and transitional care facilities, senior housing communities and specialty hospitals. Some communities are leased to operators, while others are run by third-party managers in its senior housing …
SBA owns and operates wireless towers and had 45,252 communication sites at quarter end, 17,340 in the United States and its territories and 27,912 internationally. Site leasing revenue grew 1.4% to $665.4 million. Site development revenue declined to $48.5 million from $75.9 million, taking …
Operating expenses rose to $30.3 million from $25.4 million. Other income, net, increased to $4.1 million from $3.0 million, mainly on interest earned on IPO proceeds.
The San Jose medical device company develops procedural solutions for compromised bone, with products centered on the sacroiliac joint and the spinopelvic region. It has supported physicians in more than 160,000 procedures since 2009.
Sinda is an exploration-stage company that holds five contiguousMiningconcessions in Guanajuato, Mexico, covering a high-grade silver and gold discovery. It has no revenue, and its filing reports only operating expenses, which rose to $17.0 million from $2.7 million.
Rental income dropped to $4.5 million from $24.2 million after shopping center sales, while fee and other income rose to $4.1 million from $2.9 million. The fees come from services provided to the property owner it spun off in October 2024.
Syndax is a commercial-stage biopharmaceutical company focused on cancer. Revuforj is a menin inhibitor for relapsed or refractory acute leukemia with KMT2A or NPM1 alterations, while Niktimvo treats chronic graft-versus-host disease and is commercialized with a partner that books the sales.
The company develops at-home pneumatic compression therapy for lymphedema, including the Flexitouch and Nimbl systems, and sells the AffloVest airway clearance device. Lymphedema revenue increased $9.5 million to $81.8 million, a 13.1% gain and about 11% higher than the second quarter.
The company provides aviation aftermarket services, including repair and overhaul of auxiliary power units (APUs) and heat exchangers, as well as trading, leasing and distribution of aircraft parts.Operating Incomereached $9.0 million, or 16.3% of revenue, versus $5.3 million, or 11.4%.
Please wait processing your request...